Definitive treatment patterns and survival in stage II non-small cell lung cancer

被引:3
|
作者
Yan, Sherry X. [1 ]
Qureshi, Muhammad M. [2 ,3 ]
Suzuki, Kei [3 ,4 ]
Dyer, Michael [2 ,3 ]
Truong, Minh Tam [2 ,3 ]
Litle, Virginia [3 ,4 ]
Mak, Kimberley S. [2 ,3 ]
机构
[1] Boston Med Ctr, One Boston Med Ctr Pl, Boston, MA 02118 USA
[2] Boston Med Ctr, Dept Radiat Oncol, 830 Harrison Ave, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, 72 E Concord St, Boston, MA 02118 USA
[4] Boston Med Ctr, Dept Surg, Div Thorac Surg, 830 Harrison Ave,3rd Floor, Boston, MA 02118 USA
关键词
Non-small cell lung cancer; Treatment patterns; Survival; Surgery; Radiotherapy; BODY RADIATION-THERAPY; PHASE-III; TNM CLASSIFICATION; UNITED-STATES; FRACTIONATED RADIOTHERAPY; TRIAL; CONCURRENT; MANAGEMENT; PROPOSALS; GROUPINGS;
D O I
10.1016/j.lungcan.2018.07.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This study delineated definitive treatment patterns for Stage II non-small cell lung cancer (NSCLC) in the United States and evaluated survival by treatment approach. Materials and Methods: Patients with clinically-staged Stage II NSCLC treated with surgery-based therapy, chemoradiation, conventionally-fractionated radiation (CFR), or stereotactic body radiotherapy (SBRT) were identified using the National Cancer Database (NCDB). Median survival was estimated using Kaplan-Meier analysis. Crude and adjusted hazard ratios (HR) and 95% confidence intervals were computed using Cox regression modeling. Results: Between 2004-2012, 19,749 patients met study criteria: 13,382 (67.8%) underwent surgery-based treatment, 4,310 (21.8%) received chemoradiation, 1,606 (8.1%) received CFR, and 451 (2.3%) received SBRT. Surgery and SBRT utilization increased over time while CFR and chemoradiation decreased (all p < 0.002). Patients receiving radiation-based treatments were older, with more comorbidities, and higher T/N stage (all p < 0.0001). With median follow-up of 25.2 months, median survival was 51.6, 23.3, 15.4, and 23.7 months for surgery-based treatment, chemoradiation, CFR, and SBRT, respectively (p < 0.0001). On multivariate analysis, chemoradiation (HR 1.67 [1.59-1.75], p < 0.0001), CFR (HR 2.38 [2.22-2.55], p < 0.0001), and SBRT (HR 1.76 [1.53-2.01], p < 0.0001) were associated with decreased survival versus surgery-based treatment. CFR was associated with decreased survival versus chemoradiation (HR 1.52 [1.41-1.63], p < 0.0001) and SBRT (HR 1.39 [1.19-1.61], p < 0.0001). SBRT was associated with similar survival versus chemoradiation (HR 1.10 [0.95-1.27], p = 0.212). Conclusion: NCDB data demonstrate increasing use of surgery-based treatments and SBRT for Stage II NSCLC over time. Radiation-based therapies were associated with decreased survival compared to surgery. CFR was associated with decreased survival compared to chemoradiation and SBRT.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 50 条
  • [41] SURVIVAL IN COPD PATIENTS WITH STAGE 1 NON-SMALL CELL LUNG CANCER
    Thiruchelvam, Nirosshan
    Sarda, Yash
    Han, Xiaozhen
    Wang, Xiaofeng
    Mazzone, Peter
    CHEST, 2020, 158 (04) : 1463A - 1463A
  • [42] Post Surgical Survival for Stage I Non-Small Cell Lung Cancer
    Rocha Quintana, Andy
    Rodriguez Larraburu, Elianne
    FINLAY, 2011, 1 (03): : 192 - 201
  • [43] Surgical treatment of stage IV non-small cell lung cancer
    Kawano, Daigo
    Takeo, Sadanori
    Katsura, Masakazu
    Tsukamoto, Shuichi
    Masuyama, Eri
    Nakaji, Yu
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2012, 14 (02) : 167 - 170
  • [44] Surgical treatment of stage III non-small cell lung cancer
    Orlowski, TM
    Szczesny, TJ
    LUNG CANCER, 2001, 34 : S137 - S143
  • [45] Advances in the Treatment of Stage III Non-Small Cell Lung Cancer
    Myall, Nathaniel J.
    Das, Millie
    CLINICS IN CHEST MEDICINE, 2020, 41 (02) : 211 - +
  • [46] Surgical treatment for early stage non-small cell lung cancer
    Raman, Vignesh
    Yang, Chi-Fu Jeffrey
    Deng, John Z.
    D'Amico, Thomas A.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S898 - S904
  • [47] Survival and risk model for stage IB non-small cell lung cancer
    Padilla, J
    Calvo, V
    Peñalver, JC
    Zarza, AG
    Pastor, J
    Blasco, E
    París, F
    LUNG CANCER, 2002, 36 (01) : 43 - 48
  • [48] Multimodality treatment in advanced stage non-small cell lung cancer
    Klikovits, T.
    Hoda, M. A.
    Ghanim, B.
    Aigner, C.
    Taghavi, S.
    Lang, G.
    Matilla, J.
    Klepetko, W.
    WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 (17-18) : A21 - A21
  • [49] Guidelines on treatment of stage IIIB non-small cell lung cancer
    Jett, JR
    Scott, WJ
    Rivera, MP
    Sause, WT
    CHEST, 2003, 123 (01) : 221S - 225S
  • [50] Postrecurrence survival in patients with stage I non-small cell lung cancer
    Nakagawa, Tatsuo
    Okumura, Norihito
    Ohata, Keiji
    Igai, Hitoshi
    Matsuoka, Tomoaki
    Kameyama, Kotaro
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2008, 34 (03) : 499 - 504